Welcome to the March 2023 edition of the HealthTech Activator (HTA) Monthly Wrap.
This month we share a blog post from Angel Association New Zealand (AANZ) discussing angel investment in Aotearoa and the role AANZ and its members play in early-stage investments.
We also feature upcoming April and May HTA events, including our new Health Economics workshop that has only a few spots left. If an event is full, you can still join a waitlist in case of cancellation, and this also helps us to assess demand for organising more workshops on a topic.
We’re planning online events for June covering regulatory, market validation, and reimbursement topics. These events will be listed in April, but you can express your interest or suggest other events you’d like to see using this form.
Read on for more information and links to sector news from the past month, and if you have any questions, comments, or suggestions to improve this newsletter, we would love to hear from you! As always, thanks for subscribing.
HTA blog
Do You Need an Angel?
Suse Reynolds, Angel Association of NZ
Suse Reynolds, Executive Chair of Angel Association New Zealand (AANZ), discusses the role of angel investment, AANZ as a resource for all stakeholders, and some thoughts on the current investment climate.
4 April 2023, Auckland & 25 May 2023, Christchurch | Facilitated by Dan Hansen and Shaun Wilson
Executing on sales is never a straightforward process, but the complex nature of healthtech supply chains can make health a tougher sector to succeed in than most. This new full day HTA workshop focuses on the principles of sales planning and strategy, to provide key knowledge and frameworks for understanding the sales process.
27 April 2023, Auckland | Facilitated by Jai Basrur
Our next HTA valuation workshop is ideal for healthtech business founders wanting to improve their understanding of company valuations and the role they play in capital raising. Run by Jai Basrur from CGB Consulting, this in-person workshop provides an overview of the principles and techniques involved in valuing a company - including hands-on exercises to familiarise attendees with using valuation methods.
3 May 2023, Auckland | Facilitated by Natalia Lopez and Yaara Yarmut
This regulatory workshop is provided in collaboration with Te Tītoki Mataora and is hosted at the Auckland Bioengineering Institute (ABI). Aimed at pre-spinout research groups and early-stage startups, this workshop covers the fundamentals of quality and regulatory considerations for medical devices.
Increasing the Value of your Healthtech Company Workshop
9 May 2023, Christchurch | Facilitated by Kate Wilson and Jai Basrur
This workshop is ideal for earlier-stage healthtech businesses seeking to develop strategies for leveraging their existing and future intangible assets to maximise value. It provides participants with an overview of the relevant principles, concepts, and practical considerations for bolstering the value of their healthtech business.
23 May 2023, Auckland | Facilitated by Abbas Al-Murrani
Understand the drivers and processes used to determine economic value and a health system’s willingness to pay for a healthcare product.
This highly interactive workshop is intended for decision-makers and organisations wanting to systematically compare technologies, access new markets and secure reimbursement strategies across a number of healthcare environments and systems. The workshop is co-produced with Te Tītoki Mataora, the Medtech Research Translator.
The Digital Medicine Society (DiME), in collaboration with the FDA and other stakeholders, has developed three interactive toolkits to aid understanding of US federal regulatory pathways (Digital Medicine Society).
BioViros has opened their new lab at the Gracefield Innovation Quarter for the development of lentiviral vectors used in the production of cell therapies (27 February, NBR).
Nelson-based Kimer Med discuss their ongoing development of a broad spectrum anti-viral, and their work towards in vivo studies following the opening of their new lab space in 2022 (6 March, RNZ).
Brian Ward describes Aroa Biosurgery’s journey from idea to a $64m annual revenue company in 15 years, and the expectation of $100m+ revenues in the next couple of years (6 March, NBR).
Patients, family, and their clinician speak about a CRISPR therapeutic trial targeting hereditary amyloidosis that took place in NZ, with early results suggesting all participants may be cured (19 March, 1News).
The RNA development platform will be co-hosted by Victoria University of Wellington and the University of Auckland, supported by the Malaghan Institute and University of Otago, funded over the next 7 years (24 March, NZ Herald).
